These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. Huntington JT; Shields JM; Der CJ; Wyatt CA; Benbow U; Slingluff CL; Brinckerhoff CE J Biol Chem; 2004 Aug; 279(32):33168-76. PubMed ID: 15184373 [TBL] [Abstract][Full Text] [Related]
23. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656 [TBL] [Abstract][Full Text] [Related]
24. Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Goodall J; Carreira S; Denat L; Kobi D; Davidson I; Nuciforo P; Sturm RA; Larue L; Goding CR Cancer Res; 2008 Oct; 68(19):7788-94. PubMed ID: 18829533 [TBL] [Abstract][Full Text] [Related]
25. Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1. Maddodi N; Bhat KM; Devi S; Zhang SC; Setaluri V J Biol Chem; 2010 Jan; 285(1):242-54. PubMed ID: 19880519 [TBL] [Abstract][Full Text] [Related]
26. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344 [TBL] [Abstract][Full Text] [Related]
27. Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses. Jiang L; Campagne C; Sundström E; Sousa P; Imran S; Seltenhammer M; Pielberg G; Olsson MJ; Egidy G; Andersson L; Golovko A BMC Cancer; 2014 Nov; 14():857. PubMed ID: 25413220 [TBL] [Abstract][Full Text] [Related]
28. RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma. Dorard C; Estrada C; Barbotin C; Larcher M; Garancher A; Leloup J; Beermann F; Baccarini M; Pouponnot C; Larue L; Eychène A; Druillennec S Nat Commun; 2017 May; 8():15262. PubMed ID: 28497782 [TBL] [Abstract][Full Text] [Related]
29. Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type INK4A in melanoma cells. Rotolo S; Diotti R; Gordon RE; Qiao RF; Yao Z; Phelps RG; Dong J Int J Cancer; 2005 May; 115(1):164-9. PubMed ID: 15657897 [TBL] [Abstract][Full Text] [Related]
30. The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. Thomson JA; Murphy K; Baker E; Sutherland GR; Parsons PG; Sturm RA; Thomson F Oncogene; 1995 Aug; 11(4):691-700. PubMed ID: 7651733 [TBL] [Abstract][Full Text] [Related]
31. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Dumaz N; Hayward R; Martin J; Ogilvie L; Hedley D; Curtin JA; Bastian BC; Springer C; Marais R Cancer Res; 2006 Oct; 66(19):9483-91. PubMed ID: 17018604 [TBL] [Abstract][Full Text] [Related]
32. Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells. Smith AG; Lim W; Pearen M; Muscat GE; Sturm RA Pigment Cell Melanoma Res; 2011 Jun; 24(3):551-63. PubMed ID: 21362156 [TBL] [Abstract][Full Text] [Related]
33. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506 [TBL] [Abstract][Full Text] [Related]
34. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Kono M; Dunn IS; Durda PJ; Butera D; Rose LB; Haggerty TJ; Benson EM; Kurnick JT Mol Cancer Res; 2006 Oct; 4(10):779-92. PubMed ID: 17050671 [TBL] [Abstract][Full Text] [Related]
35. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024 [TBL] [Abstract][Full Text] [Related]
36. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors. Ming Z; Lim SY; Kefford RF; Rizos H Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489 [TBL] [Abstract][Full Text] [Related]
37. Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. Calipel A; Lefevre G; Pouponnot C; Mouriaux F; Eychène A; Mascarelli F J Biol Chem; 2003 Oct; 278(43):42409-18. PubMed ID: 12917419 [TBL] [Abstract][Full Text] [Related]
38. Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions. Couts KL; Anderson EM; Gross MM; Sullivan K; Ahn NG Oncogene; 2013 Apr; 32(15):1959-70. PubMed ID: 22751131 [TBL] [Abstract][Full Text] [Related]
39. Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells. Calipel A; Mouriaux F; Glotin AL; Malecaze F; Faussat AM; Mascarelli F J Biol Chem; 2006 Apr; 281(14):9238-50. PubMed ID: 16452469 [TBL] [Abstract][Full Text] [Related]
40. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma. McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]